AU2022401939A1 - Anti-sost antibody pharmaceutical composition and use thereof - Google Patents
Anti-sost antibody pharmaceutical composition and use thereof Download PDFInfo
- Publication number
- AU2022401939A1 AU2022401939A1 AU2022401939A AU2022401939A AU2022401939A1 AU 2022401939 A1 AU2022401939 A1 AU 2022401939A1 AU 2022401939 A AU2022401939 A AU 2022401939A AU 2022401939 A AU2022401939 A AU 2022401939A AU 2022401939 A1 AU2022401939 A1 AU 2022401939A1
- Authority
- AU
- Australia
- Prior art keywords
- pharmaceutical composition
- antibody
- seq
- concentration
- sost
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39591—Stabilisation, fragmentation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/22—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Immunology (AREA)
- Physical Education & Sports Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Rheumatology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202111462784.6 | 2021-11-30 | ||
| CN202111462784 | 2021-11-30 | ||
| PCT/CN2022/135247 WO2023098694A1 (zh) | 2021-11-30 | 2022-11-30 | 一种抗sost抗体药物组合物及其用途 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AU2022401939A1 true AU2022401939A1 (en) | 2024-05-30 |
Family
ID=86611532
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2022401939A Pending AU2022401939A1 (en) | 2021-11-30 | 2022-11-30 | Anti-sost antibody pharmaceutical composition and use thereof |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20250011411A1 (https=) |
| EP (1) | EP4434517A4 (https=) |
| JP (1) | JP2024543931A (https=) |
| CN (1) | CN118175993A (https=) |
| AU (1) | AU2022401939A1 (https=) |
| CA (1) | CA3238868A1 (https=) |
| TW (1) | TW202330032A (https=) |
| WO (1) | WO2023098694A1 (https=) |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2011126338A (ru) * | 2008-11-28 | 2013-01-10 | Эбботт Лэборетриз | Стабильные композиции антител и способы их стабилизации |
| AR075715A1 (es) * | 2009-03-05 | 2011-04-20 | Novartis Ag | Formulacion de anticuerpo liofilizado |
| GB201112429D0 (en) * | 2011-07-19 | 2011-08-31 | Glaxo Group Ltd | Antigen-binding proteins with increased FcRn binding |
| HK1200322A1 (en) * | 2011-10-24 | 2015-08-07 | Abbvie Inc. | Immunobinders directed against sclerostin |
| SI3269735T1 (sl) | 2015-03-13 | 2020-12-31 | Jiangsu Hengrui Medicine Co. Ltd. | Protitelo proti sklerostinu, antigen-vezavni fragment in medicinska uporaba le-tega |
| GB201604124D0 (en) * | 2016-03-10 | 2016-04-27 | Ucb Biopharma Sprl | Pharmaceutical formulation |
| CN109952093B (zh) | 2017-07-27 | 2022-02-08 | 江苏恒瑞医药股份有限公司 | 一种sost抗体药物组合物及其用途 |
| EP4013786A1 (en) * | 2019-08-12 | 2022-06-22 | Amgen Inc. | Anti-sclerostin antibody formulations |
-
2022
- 2022-11-30 EP EP22900498.1A patent/EP4434517A4/en active Pending
- 2022-11-30 WO PCT/CN2022/135247 patent/WO2023098694A1/zh not_active Ceased
- 2022-11-30 CA CA3238868A patent/CA3238868A1/en active Pending
- 2022-11-30 US US18/713,590 patent/US20250011411A1/en active Pending
- 2022-11-30 TW TW111145967A patent/TW202330032A/zh unknown
- 2022-11-30 CN CN202280072603.5A patent/CN118175993A/zh active Pending
- 2022-11-30 JP JP2024531530A patent/JP2024543931A/ja active Pending
- 2022-11-30 AU AU2022401939A patent/AU2022401939A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| TW202330032A (zh) | 2023-08-01 |
| CN118175993A (zh) | 2024-06-11 |
| WO2023098694A1 (zh) | 2023-06-08 |
| US20250011411A1 (en) | 2025-01-09 |
| EP4434517A1 (en) | 2024-09-25 |
| EP4434517A4 (en) | 2025-06-25 |
| JP2024543931A (ja) | 2024-11-26 |
| CA3238868A1 (en) | 2023-06-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2024203436A1 (en) | Plasma kallikrein binding proteins and uses thereof in treating hereditary angioedema | |
| US20210046182A1 (en) | High concentration anti-c5 formulations | |
| JP4538461B2 (ja) | ヒトＩＬ−１βアンタゴニスト | |
| CN110538321B (zh) | 一种cd47抗体药物组合物及其用途 | |
| AU2024203126A1 (en) | Antibody formulation | |
| JP2026053516A (ja) | バイオ医薬組成物 | |
| TWI833690B (zh) | 低黏度、高濃度之依伏庫單抗調配物及其製備方法 | |
| WO2020094122A1 (zh) | 一种TGF-β受体融合蛋白药物组合物及其用途 | |
| IL205257A (en) | Isolated monoclonal antibody associated with the epitope of a respiratory syncytial virus strain a2 virus and various aspects related to this antibody | |
| EP3659586B1 (en) | Sost antibody pharmaceutical composition and uses thereof | |
| US20220089704A1 (en) | Humanized and stabilized fc5 variants for enhancement of blood brain barrier transport | |
| US20250034257A1 (en) | Stable high concentration arginine formulations containing pd-1 antibody and methods of use thereof | |
| KR20220143882A (ko) | 항-il-4r 항체를 함유하는 약학적 조성물 및 이의 용도 | |
| TW201143789A (en) | Antigen binding proteins | |
| JP7641908B2 (ja) | Ｉｌ－５に対する抗体を含有する医薬組成物及びその使用 | |
| EP4624493A1 (en) | Pharmaceutical composition comprising bispecific antibody specifically binding to hgfr and egfr | |
| TW201902518A (zh) | 一種含c-Met抗體藥物偶聯物的醫藥組成物及其用途 | |
| EP4257603A1 (en) | Pharmaceutical composition comprising anti-connective tissue growth factor antibody | |
| AU2022401939A1 (en) | Anti-sost antibody pharmaceutical composition and use thereof | |
| AU2025201510A1 (en) | Preparation comprising anti-PD-1/HER2 bispecific antibody, and preparation method therefor and use thereof | |
| CA3121291A1 (en) | Cd40 antibody pharmaceutical composition and use thereof | |
| AU2022332510A1 (en) | Pharmaceutical composition containing fusion protein | |
| CN115227813A (zh) | 一种含抗Abeta抗体的药物组合物 | |
| US20220204613A1 (en) | Anti-cd47 antibodies and uses thereof | |
| CN120437287A (zh) | 一种包含特异性结合gucy2c和cd3的双特异性抗体的药物组合物 |